Catheter Ablation News and Research

RSS

Endosense, Siemens Healthcare enter joint catheter ablation development project

Endosense, a Swiss medical technology company, and Siemens Healthcare, one of the world's largest suppliers to the healthcare industry, have agreed to commence a joint development project intended to integrate the contact-force data provided by Endosense's TactiCath® force-sensing ablation catheter with Siemens' electrophysiology solutions.

14 Jan 2011

Endosense initiates enrollment in TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation

Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.

12 Jan 2011

nContact Surgical removes 'Surgical' from company name

nContact Surgical, Inc., a cardiac ablation device manufacturer, announced today that it is changing the name under which it operates from nContact Surgical, Inc. to nContact, Inc. As the pioneer of interdisciplinary epicardial and endocardial cardiac ablation, the change represents the Company's further evolution towards closed chest approaches to treating common cardiac arrhythmias.

10 Jan 2011

Sentara Heart Hospital commences procedures in AtriCure DEEP AF feasibility trial

Sentara Heart Hospital is breaking new ground in cardiac care and treatment. Surgeons and Cardiologists at Sentara Heart Hospital are first to begin enrolling and performing trial cases in the AtriCure DEEP AF feasibility trial. The first procedure in the country was performed in a new, state-of-the-art hybrid operating room at Sentara Heart Hospital by Jonathan Philpott, M.D., Director of the Sentara Atrial Fibrillation Surgery Program, Ian Woollett, M.D., and John Onufer, M.D., Medical Director of Cardiac Electrophysiology.

3 Dec 2010

AtriCure initiates enrollment in DEEP AF feasibility trial

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, announced initial patient enrollment in its DEEP AF feasibility trial. The first procedure was performed in a new, state-of-the-art hybrid room at Sentara Norfolk General Hospital in Norfolk, Virginia by Jonathan Philpott, M.D., Director of the Sentara Atrial Fibrillation Surgery Program, Ian Woollett, M.D., and John Onufer, M.D., Medical Director of Cardiac Electrophysiology.

3 Dec 2010

NAVISTAR THERMOCOOL Catheter improves quality of life in patients with atrial fibrillation

According to data appearing today in Circulation Cardiovascular Quality and Outcomes, patients with a common heart rhythm disorder, called atrial fibrillation, who were treated with catheter ablation using the NAVISTAR THERMOCOOL Catheter, reported markedly fewer symptoms and substantially improved quality of life than patients treated with antiarrhythmia drugs at one year.

18 Nov 2010

World's first remote heart procedure using robotic arm alongside 3-D mapping

The world's first remote heart procedure, using a robotic arm alongside 3-D mapping, is due to take place at Glenfield Hospital in Leicester.

15 Nov 2010

New techniques to stop ventricular arrhythmias in high-risk patients

New techniques now being used at UCLA allow doctors to more precisely target certain areas of the heart to stop ventricular arrhythmias — serious abnormal rhythms in the heart's lower chambers — in high-risk patients.

9 Nov 2010

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

The North American Center for Continuing Medical Education, LLC , in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced several key sessions on the treatment of atrial fibrillation at the upcoming Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, to be held December 9-11, 2010, at the Washington Hilton in Washington, DC.

3 Nov 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

Catheter ablation benefits atrial fibrillation patients younger than 45

Patients under age 45 had fewer major complications than older patients and comparable improvement after a medical procedure to treat irregular heartbeat, or arrhythmia, in a study reported in Circulation: Arrhythmia and Electrophysiology, an American Heart Association journal.

22 Sep 2010

Stereotaxis highlights clinical outcomes of Niobe Magnetic Navigation System in VT ablation

Stereotaxis, Inc. highlighted significant new additions to the body of evidence demonstrating exceptional clinical outcomes achieved with its Niobe® Magnetic Navigation System in ventricular tachycardia ablation.

9 Sep 2010

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Medtronic, Inc. today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency ablation technology for the treatment of atrial fibrillation. AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.

26 Aug 2010

Patients enrolled in CLARITY-AF study

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study, comparing the efficacy, safety and efficiency of CARTO 3 System guided radiofrequency ablation using the NAVISTAR THERMOCOOL catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter (Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Jul 2010

St. Jude Medical's Therapy Cool Path Ablation Catheter receives Japanese MHLW approval

St. Jude Medical, Inc., a global medical device company, today announced Japanese Ministry of Health, Labour and Welfare approval and reimbursement approval of its Therapy Cool Path Ablation Catheter. This marks the company's first entry into the irrigated catheter ablation market in Japan.

25 Jun 2010

Medtronic's anatomically-designed ablation catheters reduce lab time for PVI

Data from the FAST-PVI study, supported by Medtronic, Inc., shows lab time using anatomically-designed ablation catheters are more than one-third (35 percent) faster than traditional point-by-point focal ablation procedures in achieving pulmonary vein isolation (PVI). PVI is the cornerstone catheter procedure to treat paroxysmal atrial fibrillation (PAF).

19 Jun 2010

St. Jude Medical's Therapy Cool Flex Ablation Catheter granted European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of the Therapy™ Cool Flex™ Ablation Catheter at the 17th World Congress in Cardiac Electrophysiology and Cardiac Techniques (CardioStim). The ablation catheter is the industry's first to have a fully-irrigated and flexible tip, which can potentially improve the safety and efficacy of cardiac ablation procedures.

18 Jun 2010

St. Jude Medical's EnSite Contact Technology platform receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of the EnSite Contact™ Technology platform at the 17th World Congress in Cardiac Electrophysiology and Cardiac Techniques (CardioStim).

17 Jun 2010

Endosense launches ProForce Registry Study of TactiCath force-sensing ablation catheter

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment of the first patients in its ProForce Registry. The news marks the launch of the ProForce Registry Study, an international, single arm, multi-center, post-market trial of Endosense's TactiCath force-sensing ablation catheter.

15 Jun 2010

Endosense awards DATATRAK first two EFFICAS studies

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that medical technology company Endosense has awarded DATATRAK the first two studies in the EFFICAS study series. The EFFICAS studies are intended to demonstrate that the use of contact force control during cardiac ablation utilizing Endosense's TactiCath® force-sensing catheter results in superior outcomes as compared to ablations performed without a force sensor.

14 Jun 2010